NCT07193550View on ClinicalTrials.gov

A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

70

Participants

Timeline

Start Date

May 31, 2026

Primary Completion Date

October 31, 2029

Study Completion Date

October 31, 2031

Conditions

Bone Sarcomas

Interventions

DRUG

Zanzalintinib

Participants will take zanzalintinib 100mg daily by mouth

Trial Locations (1)

77030

The University of Texas M. D. Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Exelixis

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER